AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33471853 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of RIs with analyzers and those from other countries
Number of subjects: 1227
Study 32936895 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological age-grading system based on ovarian morphology
Number of subjects: 0
Study 32294316 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful CTO PCI (SPCI)
Number of subjects: 302
Study 32294316 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed PCI (FPCI)
Number of subjects: 302
Study 32294316 — intervention group
Group type: COMPARATOR
Intervention: No-CTO PCI (NPCI)
Number of subjects: 302
Study 32132506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy in PHC group
Number of subjects: 170
Study 32132506 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticoduodenectomy in non-PHC group
Number of subjects: 170
Study 36191734 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute instant meditation practice using a mobile app (Group A)
Number of subjects: 43
Study 36191734 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day app-based mindfulness meditation (Group B)
Number of subjects: 43
Study 36191734 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Group C)
Number of subjects: 43
Study 34213861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 295
Study 34213861 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 295
Study 34213861 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Number of subjects: 295
Study 32998708 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfetalness
Number of subjects: 26485
Study 36302965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (16 IU, administered morning and night for 12 weeks)
Number of subjects: 87
Study 36302965 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray (administered morning and night for 12 weeks)
Number of subjects: 87
Study 33164114 — intervention group
Group type: EXPERIMENTAL
Intervention: RIRS single-use ureteroscope
Number of subjects: 158
Study 33164114 — intervention group
Group type: COMPARATOR
Intervention: ESWL
Number of subjects: 158
Study 32052341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy
Number of subjects: 366
Study 32052341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept with chemotherapy
Number of subjects: 366
Study 32052341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab followed by aflibercept
Number of subjects: 366
Study 32052341 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line bevacizumab
Number of subjects: 366
Study 36121843 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibersol-2 low dose (2.5g)
Number of subjects: 60
Study 36121843 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibersol-2 high dose (5g)
Number of subjects: 60
Study 36121843 — intervention group
Group type: COMPARATOR
Intervention: Diarrheal children
Number of subjects: 60
Study 36121843 — intervention group
Group type: COMPARATOR
Intervention: Diarrheal and healthy children
Number of subjects: 60
Study 34342032 — intervention group
Group type: EXPERIMENTAL
Intervention: MVMR‐Robust
Number of subjects: 0
Study 34342032 — intervention group
Group type: EXPERIMENTAL
Intervention: MVMR‐Lasso
Number of subjects: 0
Study 34342032 — intervention group
Group type: EXPERIMENTAL
Intervention: MVMR‐Median
Number of subjects: 0
Study 32545112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cork fish extract (Pujimin Plus)
Number of subjects: 34
Study 32545112 — intervention group
Group type: COMPARATOR
Intervention: Control (no cork fish extract)
Number of subjects: 34
Study 34643960 — intervention group
Group type: EXPERIMENTAL
Intervention: CHRT-SR7
Number of subjects: 788
Study 34518158 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 102
Study 34518158 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 102
Study 32912616 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 0
Study 32912616 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 36181505 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-radiological model based on peak enhancement phase, tumor location, alpha-fetoprotein, cancer antigen (CA)-125, CA724 levels, CT-based Tstage, and arterial phase CT values.
Number of subjects: 461
Study 33185112 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated binge drinking (4-5 drink equivalent in <2 h)
Number of subjects: 22
Study 36336989 — intervention group
Group type: COMPARATOR
Intervention: Hydroxypropyl chitosan-based 80 mg/g ciclopirox nail lacquer
Number of subjects: 381
Study 33743622 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (initial five-day structured training and home practice for 90 days)
Number of subjects: 121
Study 33743622 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (no yoga intervention)
Number of subjects: 121
Study 35946753 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink (ED) protocol
Number of subjects: 28
Study 35946753 — intervention group
Group type: COMPARATOR
Intervention: Placebo protocol (250 mL of water)
Number of subjects: 28
Study 33844373 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol air polishing
Number of subjects: 80
Study 33844373 — intervention group
Group type: COMPARATOR
Intervention: Piezoelectric ultrasonic scaling
Number of subjects: 80
Study 33844373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 34766590 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 risk alleles (2 alleles)
Number of subjects: 11930
Study 34766590 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 risk alleles (1 allele)
Number of subjects: 11930
Study 34766590 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 risk alleles (per allele)
Number of subjects: 11930
Study 36314965 — intervention group
Group type: EXPERIMENTAL
Intervention: Audibility-based descriptions
Number of subjects: 143
Study 36314965 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based descriptions
Number of subjects: 143
Study 36314965 — intervention group
Group type: COMPARATOR
Intervention: Classification-based descriptions
Number of subjects: 143
Study 36314965 — intervention group
Group type: EXPERIMENTAL
Intervention: Audibility-based and simulation-based groups
Number of subjects: 143
Study 34397596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Feeding (SF)
Number of subjects: 62
Study 34397596 — intervention group
Group type: COMPARATOR
Intervention: Continuous Feeding (CF)
Number of subjects: 62
Study 33123089 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Medical Appointments with mindfulness (six 2‐h programmed SMAs held fortnightly)
Number of subjects: 18
Study 33123089 — intervention group
Group type: COMPARATOR
Intervention: Usual care from healthcare providers
Number of subjects: 18
Study 35619802 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary program for managing TB and DM
Number of subjects: 120
Study 35619802 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-physician health workers training
Number of subjects: 120
Study 33629490 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin levels of 70–89 g/l at 6+0–13+6 weeks
Number of subjects: 11976
Study 33629490 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin levels at 26–30 weeks of gestation
Number of subjects: 11976
Study 33629490 — intervention group
Group type: COMPARATOR
Intervention: Haemoglobin levels of 110–129 g/l at 6+0–13+6 weeks
Number of subjects: 11976
Study 33629490 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin levels at 6+0–13+6 weeks and 26–30 weeks
Number of subjects: 11976
Study 32426888 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active instruction (20 minutes, 38% heart rate reserve)
Number of subjects: 51
Study 32426888 — intervention group
Group type: COMPARATOR
Intervention: Conventional sedentary instruction (21% heart rate reserve)
Number of subjects: 51
Study 32426888 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active instruction
Number of subjects: 51
Study 35421865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 209
Study 35421865 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐SE score
Number of subjects: 209
Study 35421865 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐SE stages
Number of subjects: 209
Study 35988513 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 88
Study 35988513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 33197076 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact on gastrointestinal symptoms
Number of subjects: 5157
Study 33197076 — intervention group
Group type: EXPERIMENTAL
Intervention: FD-IBS overlap syndrome
Number of subjects: 5157
Study 33197076 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological disease comorbidity and stress at work/school
Number of subjects: 5157
Study 33197076 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age, commuting by public transport, work/study from home
Number of subjects: 5157
Study 35168560 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by 6 months of oral uracil and tegafur plus leucovorin (UFT/LV)
Number of subjects: 1902
Study 35168560 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1902
Study 34886299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (50 mg intravenously)
Number of subjects: 136
Study 34886299 — intervention group
Group type: COMPARATOR
Intervention: Entonox® (50% nitrous oxide)
Number of subjects: 136
Study 32553875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Navigation System (DNS)
Number of subjects: 20
Study 32553875 — intervention group
Group type: COMPARATOR
Intervention: Manual Approach (MA)
Number of subjects: 20
Study 35260735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical immobilization using a cervical collar (collar group)
Number of subjects: 170
Study 35260735 — intervention group
Group type: COMPARATOR
Intervention: No cervical immobilization (control group)
Number of subjects: 170
Study 33148311 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS) integrated into computerized physician order entry (CPOE)
Number of subjects: 280
Study 33922546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium glucose cotransporter 2 inhibitors (SGLT2i)
Number of subjects: 0
Study 34477120 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 128
Study 34477120 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 128
Study 35715681 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Macrogol-based solution the day prior to examination (Regimen A)
Number of subjects: 180
Study 35715681 — intervention group
Group type: COMPARATOR
Intervention: Fractionated dose of Macrogol-based solution 2 days before examination (Regimen B)
Number of subjects: 180
Study 35715681 — intervention group
Group type: COMPARATOR
Intervention: Fractionated dose of Macrogol-based solution 3 days before examination (Regimen C)
Number of subjects: 180
Study 37653386 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental intervention (E)
Number of subjects: 600
Study 37653386 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention (I)
Number of subjects: 600
Study 37653386 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental plus individual intervention (E+I)
Number of subjects: 600
Study 37653386 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control group (C)
Number of subjects: 600
Study 34242311 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil organic carbon (SOC) content and its distribution in water-stable aggregates (WAS)
Number of subjects: 12
Study 34242311 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fractionation by size-density of macroorganic matter into light (LF), intermediate (IF), and heavy (HF) fractions
Number of subjects: 12
Study 34242311 — intervention group
Group type: EXPERIMENTAL
Intervention: High yields associated with high C content in stable aggregates
Number of subjects: 12
Study 34242311 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of organic fertilizers less recalcitrant
Number of subjects: 12
Study 36260533 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 8
Study 36260533 — intervention group
Group type: COMPARATOR
Intervention: Feeding alone
Number of subjects: 8
Study 33871616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron
Number of subjects: 1846
Study 33871616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rehydration
Number of subjects: 1846
Study 33871616 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 1846
Study 33871616 — intervention group
Group type: COMPARATOR
Intervention: Clinical Dehydration Scale score (mild to moderate vs none)
Number of subjects: 1846
Study 33871616 — intervention group
Group type: COMPARATOR
Intervention: Clinical Dehydration Scale score (severe vs none)
Number of subjects: 1846
Study 33871616 — intervention group
Group type: COMPARATOR
Intervention: Country (US vs Canada)
Number of subjects: 1846
Study 33871616 — intervention group
Group type: COMPARATOR
Intervention: Prior health care visit with intravenous fluids
Number of subjects: 1846
Study 33871616 — intervention group
Group type: COMPARATOR
Intervention: Frequency of vomiting (per 5 episodes)
Number of subjects: 1846
Study 36370589 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring with a respiratory volume monitor from admission to PACU until the earlier of 48 h after surgery or discharge
Number of subjects: 292
Study 33579615 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (sensorimotor and alpha rhythm feedback for 8 weeks)
Number of subjects: 80
Study 33579615 — intervention group
Group type: COMPARATOR
Intervention: Telephone support (control group, N = 20)
Number of subjects: 80
Study 32496074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic/lockdown group
Number of subjects: 2006
Study 32496074 — intervention group
Group type: COMPARATOR
Intervention: Prelockdown prepandemic group
Number of subjects: 2006
Study 35287511 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D Financial Toolkit (online financial and health insurance education toolkit)
Number of subjects: 39
Study 35287511 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 39
Study 32418845 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 141
Study 34960061 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-Plasma tablets (approximately 100 billion cells/day) for 8 weeks
Number of subjects: 320
Study 34960061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 32316993 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite molecular testing using GeneXpert Edge, process redesign to facilitate same-day TB diagnosis and treatment, and performance feedback
Number of subjects: 20
Study 32316993 — intervention group
Group type: COMPARATOR
Intervention: Routine care (onsite sputum smear microscopy plus referral of sputum samples to Xpert testing sites)
Number of subjects: 20
Study 32316993 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite molecular testing using GeneXpert Edge
Number of subjects: 20
Study 32316993 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 20
Study 34995992 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy for 8-12 weeks
Number of subjects: 85
Study 32490758 — intervention group
Group type: EXPERIMENTAL
Intervention: Progress feedback group
Number of subjects: 159
Study 32490758 — intervention group
Group type: COMPARATOR
Intervention: Non-feedback group
Number of subjects: 159
Study 35567598 — intervention group
Group type: EXPERIMENTAL
Intervention: HNP-3
Number of subjects: 66
Study 35567598 — intervention group
Group type: EXPERIMENTAL
Intervention: hBD-2
Number of subjects: 66
Study 35567598 — intervention group
Group type: EXPERIMENTAL
Intervention: LL-37
Number of subjects: 66
Study 34843068 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir treatment
Number of subjects: 161
Study 35212574 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 1910
Study 35212574 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-front cytoreductive nephrectomy (uCN)
Number of subjects: 1910
Study 35212574 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred cytoreductive nephrectomy (dCN)
Number of subjects: 1910
Study 35212574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CN) with systemic therapy
Number of subjects: 1910
Study 34107013 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg once daily (QD)
Number of subjects: 250
Study 33021715 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug and lifestyle intervention therapies
Number of subjects: 2912
Study 33021715 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive drug intervention therapy
Number of subjects: 2912
Study 35841009 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills training based on self-care (8 sessions)
Number of subjects: 60
Study 35841009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 33530473 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG recording device with artefact correction methods (1, 3, and 6% missed beats)
Number of subjects: 17
Study 33530473 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar H7 recording device
Number of subjects: 17
Study 32063109 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (two 600 mg tablets)
Number of subjects: 32
Study 32063109 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 32
Study 36349391 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 60
Study 36349391 — intervention group
Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 60
Study 33632752 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 918
Study 33632752 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive ablative therapy to prostate±pelvic lymph node dissection (PLND)
Number of subjects: 918
Study 33632752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive radical prostatectomy±PLND OR prostate radiotherapy±pelvic lymph node radiotherapy (PLNRT)
Number of subjects: 918
Study 33632752 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms will receive standard systemic therapy with ADT±upfront systemic chemotherapy or androgen receptor agents.
Number of subjects: 918
Study 33026741 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta‐1b plus lopinavir‐ritonavir
Number of subjects: 95
Study 33026741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 33026741 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta‐1b plus lopinavir‐ritonavir (within 7 days after symptom onset)
Number of subjects: 95
Study 33900213 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (PNB)
Number of subjects: 197
Study 35956235 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention conducted one month after bariatric surgery
Number of subjects: 43
Study 35956235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 43
Study 33451959 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat straw chopped at 1 mm GMPL (fine PS)
Number of subjects: 48
Study 33451959 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat straw at 4 mm GMPL (medium PS)
Number of subjects: 48
Study 33451959 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat straw at 7 mm GMPL (long PS)
Number of subjects: 48
Study 33451959 — intervention group
Group type: COMPARATOR
Intervention: Starter without wheat straw supplementation (CON)
Number of subjects: 48
Study 34627871 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution of hydronephrosis
Number of subjects: 220
Study 34627871 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution of pain
Number of subjects: 220
Study 33526484 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxfendazole (0.5 to 60 mg/kg)
Number of subjects: 0
Study 33526484 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxfendazole metabolites (oxfendazole sulfone and fenbendazole)
Number of subjects: 0
Study 36440393 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent Supported Housing (ISH)
Number of subjects: 141
Study 36440393 — intervention group
Group type: COMPARATOR
Intervention: Housing as usual (HAU)
Number of subjects: 141
Study 34018413 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence testing for rickettsial infections
Number of subjects: 2360
Study 34018413 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence testing for spotted fever group rickettsiae
Number of subjects: 2360
Study 34018413 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence testing for scrub typhus
Number of subjects: 2360
Study 34018413 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence testing for typhus group rickettsiae
Number of subjects: 2360
Study 34018413 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence in Tripura
Number of subjects: 2360
Study 34018413 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence in Assam
Number of subjects: 2360
Study 34018413 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence in Meghalaya
Number of subjects: 2360
Study 34018413 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence in adults aged 18-45 years
Number of subjects: 2360
Study 33486643 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction score based on 7 factors (stoma creation, Peritoneal Cancer Index score ≥15, hyponatremia, in-hospital major complication, preoperative chemotherapy, anemia, discharge to nursing home)
Number of subjects: 1068
Study 33486643 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction score
Number of subjects: 1068